Kenvue stock barely budged after earnings, inching up about 0.3% to US$19.23, yet the quarter quietly reinforced the core bullish argument. This is a branded consumer health business that many investors view as a steady earner, and the latest numbers again put earnings quality at the center of the story. Q2 basic earnings per share of roughly US$0.24 sat on top of a trailing twelve month earnings rise of about 17%, with net profit margin sitting near 11%. The headline is clear: earnings strength, not flashy revenue growth, is what matters in this report.

Love Kenvue's steady earnings profile but want even stronger balance sheet support behind those margins? Take a look at the list of solid balance sheet and fundamentals stocks (49 results).

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$3,955m vs. US$3,839m (up about 3.0%)
• Net Income (Q2 2026 vs. Q2 2025): US$456m vs. US$420m (up about 8.6%)
• Basic EPS (Q2 2026 vs. Q2 2025): US$0.2375 vs. US$0.2189 (up about 8.5%)
• Net Profit Margin (Trailing 12 Months): 10.8% compared with 9.3% in the prior year period (up 1.5 percentage points)

Prefer clear visuals instead of another dense block of earnings tables and footnotes? See Kenvue's full financial picture with an easy to scan valuation snapshot in the company report for Kenvue.

Kenvue bull case leans on resilient earnings engine

Bulls argue Kenvue is a steady consumer health compounder where margin resilience and cash like earnings matter more than fast sales growth. Q2 fits that script in some areas. Revenue moved from US$3,839m to US$3,955m, which supports the idea that the portfolio can still grow even as categories mature. Net income rose from US$420m to US$456m and basic EPS moved from US$0.2189 to US$0.2375. That lines up with the claim that operational simplification and brand focus can support earnings per share. A trailing net margin of 10.8% versus 9.3% a year earlier points to progress on efficiency and pricing discipline. The modest dividend increase to US$0.21 per share and ongoing ESG and supply chain projects also fit a long term quality narrative. The narrow EPS miss against expectations and withholding of guidance ahead of the Kimberly Clark deal sit slightly against the clean execution story.

Bear case focuses on execution, litigation and deal risk

Bears worry that Kenvue faces execution risk, legal overhang and deal uncertainty that could cap the benefit of steady earnings. The Q2 adjusted EPS miss and commentary that margins were down year on year speak directly to that concern, especially given management’s focus on simplification and supply chain upgrades. Withholding forward guidance ahead of the US$48.7b Kimberly Clark acquisition also feeds the view that visibility is limited in the near term. The appeals court move that revived Tylenol autism and ADHD litigation keeps product liability risk live for both Kenvue and its future parent. Mixed insider signals, including the General Counsel exiting a direct holding and more sells than buys over the past year, lean toward caution rather than conviction. The small 0.3% share price move after earnings suggests the market is not treating this quarter as a clear upside or downside break.

Reveal where the surface looks calm, but the multi year models start to disagree on Kenvue's path. Access the analyst estimates for Kenvue.

Stay Ahead With Kenvue And Simply Wall St

If Kenvue's steady net margin and recent Q2 earnings have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a more attractive entry point. Once you own Kenvue or other stocks, use the Portfolio Command Center to cut through noise and focus on concise, important updates that matter to your holdings. For the longer term, lean on the Community to see how other investors are thinking about catalysts, risks and portfolio positioning. By spotting hidden strengths and emerging red flags early, you give yourself a better chance to stay ahead of the market.

Seeking Alternatives Beyond Kenvue?

Fresh ideas move first. Stocks with real momentum often get caught once the crowd finally looks. Scan new themes that are under the radar for now and aim to get in early.

• Review a curated 49 high quality undervalued stocks to explore potential cash generative compounders before renewed interest tightens spreads and early pricing advantages start dropping for latecomers.
• Use the focused 55 AI infrastructure stocks to target companies wired into the AI build out and compare their staying power while these opportunities still fly mostly under institutional radars.
• Screen a hand picked 36 power grid technology and infrastructure stocks to review future grid essentials that could benefit if demand momentum builds and valuations move before most investors adjust.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.